Literature DB >> 17270507

Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis.

D Sánchez-Muñoz1, V M Castellano-Megías, M Romero-Gómez.   

Abstract

AIM: To study bcl-2 expression in ductular proliferation cholangiocytes and hepatic stellate cell activation in liver biopsies from patients with autoimmune cholangitis and primary biliary cirrhosis.
MATERIALS AND METHODS: Twenty-four primary biliary cirrhosis patients and 11 autoimmune cholangitis patients were included. Thirty-four females, average age: 52.5+/-12.6 years. We studied the presence of ductular proliferation, cholestasis, florid ductal lesion, granulomata, ductopenia and histologic stage. Patients were classified in primary biliary cirrhosis or autoimmune cholangitis according to antimitochondrial antibodies, antinuclear antibodies, smooth muscle antibody, antiGP210 and antiSP100 autoantibodies. We studied the presence of bcl-2 by monoclonal antibcl-2 antibody (clon 100, BioGenex). The presence of activated (specific antialpha-actin antibodies) and independent lobular, periportal and portal hepatic stellate cell was assessed using a semiquantitative scale.
RESULTS: Interlobular ducts bcl-2 was seen in 18 (51.4%) patients. Activated periportal hepatic stellate cell correlated with Ludwig's stage (r=0.43; n=35; p=0.01). Ten out of 15 (66.6%) patients with ductular proliferation showed positive interlobular ducts bcl-2 while bcl-2 was negative in 8 out of 20 (40%) patients without ductular proliferation; p<0.05. Bcl-2 positive patients in ductular proliferation showed a more advanced Ludwig's stage (2.33+/-0.77 versus 1.26+/-1.05; p<0.05) and a higher periportal hepatic stellate cell activation index (0.83+/-0.78 versus 0.23+/-0.43; p=0.009). No relationship was found among periportal hepatic stellate cell activation and the presence of florid ductal lesion, cholestasis, granulomata or biliary erosive necrosis. Hepatic stellate cell activation was similar in patients with either autoimmune cholangitis or primary biliary cirrhosis.
CONCLUSIONS: Periportal hepatic stellate cell activation seems to play a main role in fibrosis progression in patients with autoimmune cholestasis. Bcl-2 expression in ductular proliferation may promote hepatic stellate cell activation and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270507     DOI: 10.1016/j.dld.2006.12.004

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

Review 1.  Biology of the adult hepatic progenitor cell: "ghosts in the machine".

Authors:  Houda Darwiche; Bryon E Petersen
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Tregs: A Therapeutic Target for the Treatment of Portal Fibrosis?

Authors:  Yuhua Xue; George Michalopoulos
Journal:  Dig Dis Sci       Date:  2015-05-14       Impact factor: 3.199

3.  Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

Authors:  Emina Halilbasic; Romina Fiorotto; Peter Fickert; Hanns-Ulrich Marschall; Tarek Moustafa; Carlo Spirli; Andrea Fuchsbichler; Judith Gumhold; Dagmar Silbert; Kurt Zatloukal; Cord Langner; Uday Maitra; Helmut Denk; Alan F Hofmann; Mario Strazzabosco; Michael Trauner
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 4.  Hepatic inflammation and progressive liver fibrosis in chronic liver disease.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 5.  Long noncoding RNA H19 - a new player in the pathogenesis of liver diseases.

Authors:  Zhihong Yang; Ting Zhang; Sen Han; Praveen Kusumanchi; Nazmul Huda; Yanchao Jiang; Suthat Liangpunsakul
Journal:  Transl Res       Date:  2020-11-20       Impact factor: 10.171

6.  Bcl2 is a critical regulator of bile acid homeostasis by dictating Shp and lncRNA H19 function.

Authors:  Yuxia Zhang; Chune Liu; Olivier Barbier; Rana Smalling; Hiroyuki Tsuchiya; Sangmin Lee; Don Delker; An Zou; Curt H Hagedorn; Li Wang
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.